Baie d'Urfé, Canada

John W Gillard



Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Baie D'Urfe, CA (2006 - 2010)
  • Bale D'Urfe, CA (2010)
  • Baie D'Urfé, CA (2010 - 2016)

Company Filing History:


Years Active: 2006-2016

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of John W Gillard

Introduction

John W Gillard is a notable inventor based in Baie d'Urfé, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target proliferative disorders such as cancer. With a total of nine patents to his name, Gillard's work has the potential to impact the medical community profoundly.

Latest Patents

Gillard's latest patents include the IAP BIR domain binding compounds. One patent describes a compound of Formula I or a salt thereof, along with methods for its preparation and related methods and compositions. Another patent discloses an isomer, enantiomer, diastereoisomer, or tautomer of a compound represented by Formula I or II or a salt thereof. These compounds are designed to treat proliferative disorders, showcasing Gillard's commitment to advancing medical science.

Career Highlights

Throughout his career, John W Gillard has worked with prominent companies in the pharmaceutical industry. Notable among these are Aegera Therapeutics, Inc. and Pharmascience Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas, leading to the successful patenting of his inventions.

Collaborations

Gillard has collaborated with several talented individuals in his field. Among his coworkers are James B Jaquith and Alain Boudreault, who have contributed to his research and development efforts.

Conclusion

John W Gillard's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to pave the way for advancements in the treatment of serious medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…